"We plan to introduce a new multi-target pipeline"
[by Ji, Yong Jun] Aprilbio announced on April 8 that it signed a strategic memorandum of understanding (MOU) with Epsilon Molecular Engineering Inc. (EME), a Japanese company specializing in antibody and protein engineering, for the co-development of next-generation nanobody-based therapeutics. Through the integration of their respective core 온라인바카라 technologies, the two companies aim to accelerate joint research and development (R&D) efforts and advance commercialization strategies targeting the global market.
The partner company EME is a biotechnology venture spun off from Saitama University in Japan in 2016. The company possesses specialized technologies in nanobody and protein engineering. Its self-developed 온라인바카라, 'The Month,' integrates a synthetic nanobody library based on cDNA display with high-speed screening technology, enabling the rapid identification of therapeutic candidates with high affinity and specificity within just 30 business days. According to Aprilbio, this 온라인바카라 offers an effective solution for targeting molecules that are challenging to address using conventional antibody technologies.
At the core of this collaboration is Aprilbio’s proprietary 온라인바카라 technology, ‘REMAP (Recombinant and Evolved Multi-specific Antibody Proteins),’ an advanced therapeutic development 온라인바카라 designed for multi-target applications. The 온라인바카라 represents a significant advancement over the earlier ‘SAFA’ 온라인바카라, which was limited to single-target applications, and is currently being used in the development of Aprilbio’s multi-specific therapeutic candidates as well as its pipeline of antibody-drug conjugates (ADCs).
Through this collaboration, the two companies will initiate co-development efforts by incorporating EME’s high-performance nanobody candidates into Aprilbio’s REMAP 온라인바카라. By leveraging the strengths of both technologies, the partnership aims to secure global competitiveness in the field of next-generation immunotherapies and pioneer unexplored new treatment areas.
“We anticipate that the synergy between EME’s world-class nanobody discovery 온라인바카라 and our proprietary REMAP technology will enable the introduction of innovative and differentiated next-generation therapeutics for the global market,” an Aprilbio official said. “We plan to unveil a next-generation pipeline based on the REMAP 온라인바카라 in the near future.”